The use of lumacaftor/ivacaftor to treat acute deterioration in paediatric cystic fibrosis

被引：3
|
作者：
Hammond, James A. [1 ]
Connett, Gary J. [1 ]
机构：
[1] Southampton Childrens Hosp, Southampton Biomed Res Ctr, Natl Inst Hlth Res, Tremona Rd, Southampton SO16 6YD, Hants, England
来源：
PAEDIATRIC RESPIRATORY REVIEWS | 2018年 / 27卷
关键词：
Cystic fibrosis; Lumacaftor; Ivacaftor; Paediatric; SEVERE LUNG-DISEASE; AGED; 6-11; YEARS; COMBINATION THERAPY; PHE508DEL CFTR; IN-VITRO; F508DEL-CFTR; INITIATION; IVACAFTOR; EFFICACY; MUTATION;
D O I：
10.1016/j.prrv.2018.05.008
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
Lumacaftor/ivacaftor is a precision medicine targeting the defective cystic fibrosis transmembrane regulator (CFTR) protein in cystic fibrosis (CF) patients homozygous for Phe508del genotype. Whilst there is evidence for efficacy in children aged 6-11 years who are stable with good lung function, there are little data about the use of this medication for children with acute deterioration in this age group. We describe the use of this drug to treat a child with an unusually severe exacerbation of CF lung disease and review the potential of lumacaftor/ivacaftor as a rescue therapy in the paediatric CF population. Crown Copyright (C) 2018 Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码：16 / 17
页数：2
相关论文
共 50 条
  • [21] Lumacaftor/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion
    Colombo, C.
    Foppiani, A.
    Bisogno, A.
    Gambazza, S.
    Dacco, V
    Nazzari, E.
    Leone, A.
    Giana, A.
    Mari, A.
    Battezzati, A.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2021, 44 (10) : 2213 - 2218
  • [22] Multi-Omics Profiling of Lumacaftor/Ivacaftor Response in Cystic Fibrosis
    Kopp, B. T.
    Fitch, J. R.
    Zhang, S.
    Shrestha, C. L.
    Woodley, F. W.
    Hayes, D.
    White, P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [23] Combination Therapy with Lumacaftor-Ivacaftor in Cystic Fibrosis Keeping It Real
    Sala, Marc A.
    Jain, Manu
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201 (02) : 133 - 134
  • [24] Adherence to lumacaftor-ivacaftor therapy in patients with cystic fibrosis in France
    Olivereau, Lucie
    Nave, Viviane
    Garcia, Stephan
    Perceval, Marie
    Rabilloud, Muriel
    Durieu, Isabelle
    Reynaud, Quitterie
    JOURNAL OF CYSTIC FIBROSIS, 2020, 19 (03) : 402 - 406
  • [25] T-cell-mediated hypersensitivity to lumacaftor and ivacaftor in cystic fibrosis
    Semic-Jusufagic, Aida
    Ogese, Monday O.
    Edwards, Christopher
    Wilkinson, Mark
    Nissenbaum, Claire
    Lee, Tim
    Pirmohamed, Munir
    Naisbitt, Dean J.
    PEDIATRIC ALLERGY AND IMMUNOLOGY, 2022, 33 (06)
  • [26] Characterization Of Ivacaftor And Lumacaftor Using Biomap® Profiling - Implications For Cystic Fibrosis
    Velichko, S.
    Berg, E.
    Folias, A.
    Bassoni, D.
    O'Mahony, A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [27] Can Cystic Fibrosis Patients Finally Catch a Breath With Lumacaftor/Ivacaftor?
    Schneider, E. K.
    Reyes-Ortega, F.
    Li, J.
    Velkov, T.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (01) : 130 - 141
  • [28] Continuous glucose monitoring in youth with cystic fibrosis treated with lumacaftor-ivacaftor
    Li, Angel
    Vigers, Tim
    Pyle, Laura
    Zemanick, Edith
    Nadeau, Kristen
    Sagel, Scott D.
    Chan, Christine L.
    JOURNAL OF CYSTIC FIBROSIS, 2019, 18 (01) : 144 - 149
  • [29] Safety and efficacy of treatment with lumacaftor in combination with ivacaftor in younger patients with cystic fibrosis
    Cheng, Pi Chun
    Alexiou, Stamatia
    Rubenstein, Ronald C.
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2019, 13 (05) : 417 - 423
  • [30] Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects
    Kuk, Kelly
    Taylor-Cousar, Jennifer L.
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2015, 9 (06) : 313 - 326
12345